Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
Taiwan | 40 | 2021 | 2556 | 2.83 | Why? |
Bacteremia | 5 | 2019 | 1372 | 1.52 | Why? |
Emphysema | 2 | 2017 | 52 | 1.34 | Why? |
Escherichia coli Proteins | 2 | 2018 | 168 | 1.29 | Why? |
Patient Care Bundles | 2 | 2017 | 137 | 1.18 | Why? |
Catheter-Related Infections | 2 | 2017 | 381 | 1.02 | Why? |
Escherichia coli | 3 | 2018 | 1547 | 0.90 | Why? |
Coinfection | 4 | 2021 | 6820 | 0.84 | Why? |
Bacterial Infections | 5 | 2021 | 2229 | 0.80 | Why? |
Intraabdominal Infections | 1 | 2020 | 90 | 0.78 | Why? |
Sofosbuvir | 2 | 2021 | 518 | 0.77 | Why? |
Mycoses | 2 | 2021 | 589 | 0.76 | Why? |
Anti-Infective Agents | 2 | 2021 | 1766 | 0.74 | Why? |
Pulmonary Disease, Chronic Obstructive | 5 | 2019 | 3832 | 0.74 | Why? |
Salmonella | 1 | 2018 | 58 | 0.73 | Why? |
Sexually Transmitted Diseases | 3 | 2021 | 694 | 0.72 | Why? |
Thigh | 1 | 2017 | 55 | 0.72 | Why? |
Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2019 | 91 | 0.71 | Why? |
Burns, Chemical | 1 | 2017 | 16 | 0.70 | Why? |
Anti-Bacterial Agents | 11 | 2021 | 10083 | 0.70 | Why? |
Liver Abscess | 1 | 2017 | 42 | 0.70 | Why? |
Klebsiella pneumoniae | 3 | 2018 | 658 | 0.70 | Why? |
Pneumatosis Cystoides Intestinalis | 1 | 2018 | 41 | 0.70 | Why? |
Knee Injuries | 1 | 2017 | 25 | 0.69 | Why? |
Information Technology | 1 | 2020 | 278 | 0.69 | Why? |
Tetanus | 1 | 2017 | 61 | 0.66 | Why? |
Early Ambulation | 1 | 2017 | 102 | 0.65 | Why? |
Drug Resistance, Microbial | 1 | 2021 | 419 | 0.64 | Why? |
Syphilis | 1 | 2020 | 318 | 0.62 | Why? |
Chemoembolization, Therapeutic | 1 | 2017 | 144 | 0.62 | Why? |
Sepsis | 5 | 2019 | 3517 | 0.61 | Why? |
Methemoglobinemia | 1 | 2016 | 51 | 0.61 | Why? |
Communicable Diseases | 2 | 2021 | 2148 | 0.60 | Why? |
Janus Kinase Inhibitors | 1 | 2021 | 682 | 0.60 | Why? |
Pulmonary Aspergillosis | 1 | 2020 | 408 | 0.59 | Why? |
Oral Hygiene | 1 | 2017 | 137 | 0.58 | Why? |
Chlorhexidine | 1 | 2017 | 176 | 0.58 | Why? |
Staphylococcal Infections | 2 | 2017 | 1099 | 0.57 | Why? |
Methicillin-Resistant Staphylococcus aureus | 3 | 2018 | 711 | 0.57 | Why? |
Teicoplanin | 1 | 2017 | 191 | 0.57 | Why? |
Glycopeptides | 1 | 2017 | 199 | 0.56 | Why? |
Oxazines | 1 | 2016 | 279 | 0.56 | Why? |
Cephalosporins | 1 | 2017 | 250 | 0.56 | Why? |
Carbapenems | 2 | 2017 | 343 | 0.55 | Why? |
Enterobacteriaceae Infections | 2 | 2018 | 529 | 0.54 | Why? |
Vancomycin | 1 | 2017 | 328 | 0.52 | Why? |
Parenteral Nutrition | 1 | 2015 | 184 | 0.52 | Why? |
Listeriosis | 1 | 2013 | 36 | 0.52 | Why? |
Staphylococcus aureus | 2 | 2017 | 844 | 0.51 | Why? |
Rehabilitation | 1 | 2019 | 386 | 0.51 | Why? |
Government Regulation | 1 | 2020 | 842 | 0.51 | Why? |
Escherichia coli Infections | 1 | 2017 | 348 | 0.50 | Why? |
Invasive Pulmonary Aspergillosis | 1 | 2020 | 634 | 0.50 | Why? |
Listeria monocytogenes | 1 | 2013 | 68 | 0.50 | Why? |
Insurance, Health | 2 | 2019 | 634 | 0.49 | Why? |
Airway Extubation | 4 | 2019 | 403 | 0.49 | Why? |
Catheterization, Central Venous | 1 | 2017 | 458 | 0.48 | Why? |
Angiotensin II Type 1 Receptor Blockers | 1 | 2018 | 520 | 0.48 | Why? |
Abdominal Pain | 1 | 2018 | 858 | 0.48 | Why? |
Colon | 1 | 2017 | 669 | 0.47 | Why? |
Hydrogen Peroxide | 1 | 2017 | 680 | 0.47 | Why? |
Microbial Sensitivity Tests | 9 | 2018 | 2886 | 0.47 | Why? |
Pneumonia, Ventilator-Associated | 2 | 2017 | 861 | 0.47 | Why? |
Humans | 100 | 2021 | 930598 | 0.47 | Why? |
Mouthwashes | 1 | 2017 | 432 | 0.47 | Why? |
Nursing Homes | 2 | 2020 | 4155 | 0.47 | Why? |
Treatment Outcome | 18 | 2021 | 51732 | 0.46 | Why? |
Urinary Tract Infections | 1 | 2017 | 534 | 0.44 | Why? |
beta-Lactamases | 2 | 2017 | 759 | 0.44 | Why? |
Embolism, Air | 1 | 2011 | 23 | 0.44 | Why? |
Antifungal Agents | 4 | 2020 | 1828 | 0.44 | Why? |
Gastrointestinal Tract | 1 | 2019 | 1113 | 0.42 | Why? |
Staphylococcus | 1 | 2011 | 77 | 0.42 | Why? |
Abdominal Injuries | 1 | 2011 | 72 | 0.41 | Why? |
Angiotensin-Converting Enzyme Inhibitors | 2 | 2019 | 5277 | 0.41 | Why? |
Anti-Infective Agents, Local | 1 | 2017 | 520 | 0.41 | Why? |
Blood | 1 | 2011 | 274 | 0.40 | Why? |
Intensive Care Units | 14 | 2020 | 29594 | 0.40 | Why? |
Ischemia | 1 | 2017 | 901 | 0.39 | Why? |
Valine | 2 | 2021 | 359 | 0.38 | Why? |
Quality Improvement | 2 | 2018 | 2435 | 0.37 | Why? |
Network Meta-Analysis | 2 | 2021 | 426 | 0.37 | Why? |
Patient Readmission | 1 | 2018 | 1543 | 0.37 | Why? |
Civil Defense | 1 | 2020 | 1687 | 0.37 | Why? |
Swine Diseases | 1 | 2018 | 1219 | 0.36 | Why? |
Bacteriological Techniques | 1 | 2011 | 239 | 0.36 | Why? |
Wounds, Nonpenetrating | 1 | 2011 | 157 | 0.36 | Why? |
Prisons | 1 | 2017 | 980 | 0.35 | Why? |
Hand Hygiene | 1 | 2018 | 1493 | 0.35 | Why? |
Guideline Adherence | 2 | 2018 | 2309 | 0.35 | Why? |
Thrombocytopenia | 1 | 2021 | 2093 | 0.35 | Why? |
Fungemia | 1 | 2008 | 86 | 0.34 | Why? |
Carbamates | 2 | 2021 | 485 | 0.34 | Why? |
Carcinoma, Hepatocellular | 1 | 2017 | 1222 | 0.33 | Why? |
Incidence | 11 | 2021 | 25622 | 0.33 | Why? |
Encephalitis, Japanese | 1 | 2007 | 58 | 0.33 | Why? |
Pyrrolidines | 2 | 2021 | 558 | 0.33 | Why? |
Candida | 3 | 2019 | 425 | 0.33 | Why? |
Influenza, Human | 5 | 2021 | 10779 | 0.32 | Why? |
Tuberculosis | 2 | 2020 | 2895 | 0.32 | Why? |
Rhizopus | 1 | 2006 | 32 | 0.32 | Why? |
Survivors | 1 | 2019 | 2619 | 0.32 | Why? |
Long-Term Care | 4 | 2020 | 2047 | 0.31 | Why? |
Patient Safety | 1 | 2021 | 4885 | 0.31 | Why? |
Empyema, Pleural | 1 | 2006 | 46 | 0.30 | Why? |
Rhabdomyolysis | 1 | 2010 | 287 | 0.30 | Why? |
Liver Cirrhosis | 1 | 2017 | 1810 | 0.30 | Why? |
Proportional Hazards Models | 7 | 2019 | 6543 | 0.30 | Why? |
Imidazoles | 2 | 2021 | 631 | 0.29 | Why? |
Liver Neoplasms | 1 | 2017 | 1666 | 0.29 | Why? |
Dementia | 2 | 2017 | 1861 | 0.27 | Why? |
Randomized Controlled Trials as Topic | 6 | 2021 | 10649 | 0.27 | Why? |
Adrenergic beta-Antagonists | 2 | 2017 | 465 | 0.26 | Why? |
Emergency Service, Hospital | 6 | 2021 | 14232 | 0.26 | Why? |
Aged | 31 | 2020 | 215776 | 0.26 | Why? |
Pneumonia | 3 | 2018 | 5652 | 0.26 | Why? |
Coronavirus Infections | 10 | 2020 | 253789 | 0.25 | Why? |
Male | 45 | 2021 | 367725 | 0.25 | Why? |
Adenosine Monophosphate | 4 | 2021 | 5652 | 0.25 | Why? |
Alanine | 4 | 2021 | 5687 | 0.25 | Why? |
Respiratory Insufficiency | 4 | 2019 | 7301 | 0.25 | Why? |
Molecular Typing | 3 | 2018 | 280 | 0.24 | Why? |
Aspergillus | 2 | 2020 | 347 | 0.24 | Why? |
Drug Resistance, Multiple, Bacterial | 4 | 2018 | 1115 | 0.24 | Why? |
Environmental Microbiology | 2 | 2018 | 575 | 0.24 | Why? |
Myocardial Infarction | 1 | 2018 | 3361 | 0.24 | Why? |
Pneumococcal Infections | 2 | 2020 | 562 | 0.24 | Why? |
Patient Discharge | 1 | 2018 | 5696 | 0.24 | Why? |
Angiotensin Receptor Antagonists | 1 | 2019 | 3892 | 0.24 | Why? |
Kidney Failure, Chronic | 1 | 2018 | 3222 | 0.23 | Why? |
Drug Resistance, Multiple, Fungal | 2 | 2019 | 45 | 0.23 | Why? |
Pneumonia, Viral | 9 | 2020 | 243684 | 0.23 | Why? |
Dibenzothiepins | 1 | 2021 | 39 | 0.23 | Why? |
Infection Control | 4 | 2020 | 23131 | 0.23 | Why? |
APACHE | 3 | 2019 | 682 | 0.23 | Why? |
Radiography | 3 | 2017 | 1576 | 0.22 | Why? |
Echinocandins | 2 | 2019 | 139 | 0.22 | Why? |
Coronavirus | 2 | 2020 | 18339 | 0.22 | Why? |
Prognosis | 4 | 2018 | 32490 | 0.21 | Why? |
Social Control Policies | 1 | 2020 | 54 | 0.21 | Why? |
Asymptomatic Infections | 1 | 2020 | 7218 | 0.21 | Why? |
Middle Aged | 35 | 2020 | 270681 | 0.21 | Why? |
Contact Tracing | 1 | 2020 | 8448 | 0.21 | Why? |
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2006 | 526 | 0.21 | Why? |
Cobicistat | 1 | 2021 | 172 | 0.21 | Why? |
Arthus Reaction | 1 | 2019 | 1 | 0.20 | Why? |
Retrospective Studies | 17 | 2021 | 105322 | 0.20 | Why? |
Cross Infection | 5 | 2018 | 8675 | 0.20 | Why? |
Acinetobacter baumannii | 3 | 2018 | 378 | 0.20 | Why? |
Cyproheptadine | 1 | 2019 | 8 | 0.20 | Why? |
Pyrazines | 2 | 2021 | 1783 | 0.20 | Why? |
Tetracyclines | 1 | 2020 | 82 | 0.20 | Why? |
Amides | 2 | 2021 | 1864 | 0.20 | Why? |
Compliance | 1 | 2018 | 28 | 0.19 | Why? |
Morpholines | 1 | 2021 | 351 | 0.19 | Why? |
Respiration, Artificial | 5 | 2020 | 22116 | 0.19 | Why? |
Triazines | 1 | 2021 | 246 | 0.19 | Why? |
Electrophoresis, Gel, Pulsed-Field | 1 | 2018 | 78 | 0.19 | Why? |
Rome | 1 | 2020 | 497 | 0.19 | Why? |
Thrombosis | 1 | 2021 | 7504 | 0.19 | Why? |
Tetracycline Resistance | 1 | 2017 | 8 | 0.19 | Why? |
Histamine H1 Antagonists | 1 | 2019 | 79 | 0.19 | Why? |
Pandemics | 16 | 2021 | 389249 | 0.18 | Why? |
Dermatomycoses | 1 | 2019 | 55 | 0.18 | Why? |
Cefoperazone | 1 | 2017 | 6 | 0.18 | Why? |
Databases, Factual | 6 | 2018 | 6248 | 0.18 | Why? |
Immunocompromised Host | 3 | 2021 | 5150 | 0.18 | Why? |
Watchful Waiting | 1 | 2020 | 276 | 0.18 | Why? |
Fluticasone-Salmeterol Drug Combination | 1 | 2017 | 10 | 0.18 | Why? |
Budesonide, Formoterol Fumarate Drug Combination | 1 | 2017 | 7 | 0.18 | Why? |
Sulbactam | 1 | 2017 | 37 | 0.18 | Why? |
Adrenal Cortex Hormones | 3 | 2021 | 6537 | 0.18 | Why? |
Administrative Claims, Healthcare | 1 | 2018 | 124 | 0.18 | Why? |
Pseudomonas aeruginosa | 3 | 2018 | 652 | 0.18 | Why? |
Clostridium tetani | 1 | 2017 | 9 | 0.18 | Why? |
Female | 33 | 2021 | 380317 | 0.18 | Why? |
Aged, 80 and over | 17 | 2019 | 88759 | 0.18 | Why? |
Bone Cements | 1 | 2017 | 21 | 0.18 | Why? |
Methicillin | 1 | 2017 | 73 | 0.18 | Why? |
Iran | 2 | 2021 | 5467 | 0.18 | Why? |
RNA, Ribosomal, 16S | 3 | 2017 | 793 | 0.17 | Why? |
Stroke | 2 | 2018 | 8839 | 0.17 | Why? |
Analgesics, Non-Narcotic | 1 | 2019 | 164 | 0.17 | Why? |
Candidiasis, Invasive | 1 | 2019 | 107 | 0.17 | Why? |
Rupture | 1 | 2017 | 40 | 0.17 | Why? |
Cystitis | 1 | 2017 | 45 | 0.17 | Why? |
Darunavir | 1 | 2021 | 477 | 0.17 | Why? |
Propensity Score | 4 | 2019 | 2690 | 0.17 | Why? |
Penicillin Resistance | 1 | 2016 | 15 | 0.17 | Why? |
Amphotericin B | 1 | 2019 | 256 | 0.17 | Why? |
Catheters | 1 | 2017 | 93 | 0.17 | Why? |
Pneumoperitoneum | 1 | 2018 | 70 | 0.17 | Why? |
Fungi | 1 | 2021 | 471 | 0.17 | Why? |
Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.17 | Why? |
Ventilator Weaning | 2 | 2019 | 536 | 0.17 | Why? |
Geography, Medical | 1 | 2020 | 537 | 0.17 | Why? |
Clinical Trials, Phase III as Topic | 1 | 2021 | 782 | 0.17 | Why? |
Health Policy | 1 | 2017 | 6242 | 0.16 | Why? |
Gonorrhea | 1 | 2021 | 315 | 0.16 | Why? |
Japan | 2 | 2020 | 6653 | 0.16 | Why? |
Drug Therapy, Combination | 2 | 2021 | 7268 | 0.16 | Why? |
Fosfomycin | 1 | 2016 | 48 | 0.16 | Why? |
Ciprofloxacin | 1 | 2017 | 130 | 0.16 | Why? |
In Vitro Techniques | 1 | 2020 | 1027 | 0.16 | Why? |
Tongue Neoplasms | 1 | 2016 | 54 | 0.16 | Why? |
Tertiary Care Centers | 2 | 2017 | 8248 | 0.16 | Why? |
Risk Factors | 12 | 2020 | 71621 | 0.16 | Why? |
Time Factors | 8 | 2018 | 31397 | 0.16 | Why? |
Fasciitis, Necrotizing | 1 | 2016 | 56 | 0.16 | Why? |
Mucormycosis | 1 | 2006 | 832 | 0.16 | Why? |
Nitriles | 1 | 2021 | 1053 | 0.16 | Why? |
Survival Analysis | 3 | 2020 | 7592 | 0.16 | Why? |
Pulmonary Embolism | 2 | 2017 | 4775 | 0.15 | Why? |
Acetaminophen | 1 | 2019 | 326 | 0.15 | Why? |
Gastroesophageal Reflux | 1 | 2017 | 124 | 0.15 | Why? |
Antiviral Agents | 4 | 2021 | 41703 | 0.15 | Why? |
Cyanosis | 1 | 2016 | 100 | 0.15 | Why? |
Adrenergic beta-2 Receptor Agonists | 1 | 2017 | 142 | 0.15 | Why? |
Reference Values | 1 | 2018 | 795 | 0.15 | Why? |
Purines | 1 | 2021 | 816 | 0.15 | Why? |
Drug Utilization | 1 | 2021 | 619 | 0.15 | Why? |
Pyridones | 1 | 2021 | 738 | 0.15 | Why? |
Influenza A Virus, H1N1 Subtype | 1 | 2010 | 2984 | 0.14 | Why? |
Azetidines | 1 | 2021 | 722 | 0.14 | Why? |
Piperidines | 1 | 2021 | 795 | 0.14 | Why? |
Hospitals | 4 | 2019 | 11793 | 0.14 | Why? |
False Positive Reactions | 1 | 2020 | 1338 | 0.14 | Why? |
Antibodies, Monoclonal, Humanized | 3 | 2021 | 9335 | 0.14 | Why? |
Ceftriaxone | 1 | 2016 | 365 | 0.14 | Why? |
HIV Infections | 1 | 2020 | 11620 | 0.14 | Why? |
Candidiasis | 1 | 2019 | 334 | 0.14 | Why? |
Comorbidity | 7 | 2020 | 34796 | 0.14 | Why? |
Methylene Blue | 1 | 2016 | 175 | 0.14 | Why? |
Cohort Studies | 7 | 2019 | 36005 | 0.14 | Why? |
Sex Distribution | 2 | 2018 | 2083 | 0.13 | Why? |
Adult | 18 | 2020 | 244371 | 0.13 | Why? |
Calcium Channel Blockers | 1 | 2017 | 367 | 0.13 | Why? |
Delivery of Health Care | 1 | 2020 | 15909 | 0.13 | Why? |
Cannula | 1 | 2019 | 750 | 0.13 | Why? |
Betacoronavirus | 9 | 2020 | 204454 | 0.13 | Why? |
Prevalence | 4 | 2020 | 25773 | 0.13 | Why? |
Drug Synergism | 1 | 2017 | 833 | 0.13 | Why? |
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2017 | 449 | 0.13 | Why? |
Singapore | 2 | 2020 | 3641 | 0.13 | Why? |
RNA, Viral | 1 | 2021 | 32276 | 0.13 | Why? |
False Negative Reactions | 1 | 2020 | 1785 | 0.13 | Why? |
Pyrimidines | 1 | 2021 | 1557 | 0.13 | Why? |
China | 4 | 2020 | 50654 | 0.12 | Why? |
Candidemia | 1 | 2017 | 353 | 0.12 | Why? |
Fever | 2 | 2021 | 7795 | 0.12 | Why? |
Ethanol | 1 | 2018 | 533 | 0.12 | Why? |
Measles | 1 | 2020 | 608 | 0.12 | Why? |
Methylobacteriaceae | 1 | 2011 | 2 | 0.12 | Why? |
Indoles | 1 | 2021 | 1243 | 0.12 | Why? |
Klebsiella Infections | 1 | 2017 | 466 | 0.12 | Why? |
Antimicrobial Stewardship | 1 | 2021 | 931 | 0.12 | Why? |
Sulfonamides | 1 | 2021 | 1294 | 0.12 | Why? |
Bacteria | 2 | 2021 | 1897 | 0.12 | Why? |
Glucocorticoids | 2 | 2019 | 4431 | 0.12 | Why? |
Risk Assessment | 5 | 2018 | 25439 | 0.12 | Why? |
Bronchodilator Agents | 1 | 2017 | 444 | 0.12 | Why? |
Endocarditis | 1 | 2017 | 368 | 0.12 | Why? |
Protective Factors | 1 | 2018 | 1720 | 0.11 | Why? |
Age Distribution | 2 | 2018 | 3567 | 0.11 | Why? |
Myocardial Ischemia | 1 | 2018 | 781 | 0.11 | Why? |
Drug Combinations | 1 | 2021 | 3852 | 0.11 | Why? |
Fractures, Bone | 1 | 2017 | 487 | 0.11 | Why? |
Acute Kidney Injury | 2 | 2018 | 5762 | 0.11 | Why? |
Overweight | 1 | 2017 | 916 | 0.11 | Why? |
Citrobacter | 1 | 2010 | 5 | 0.11 | Why? |
Communicable Disease Control | 1 | 2020 | 29620 | 0.11 | Why? |
Pyrazoles | 1 | 2021 | 1791 | 0.11 | Why? |
Headache | 1 | 2021 | 2257 | 0.10 | Why? |
HIV | 1 | 2017 | 1116 | 0.10 | Why? |
DNA, Ribosomal | 2 | 2010 | 112 | 0.10 | Why? |
Neoplasms | 2 | 2018 | 17251 | 0.10 | Why? |
Bronchi | 1 | 2017 | 1048 | 0.10 | Why? |
Fatigue | 1 | 2021 | 2479 | 0.10 | Why? |
Nasopharyngeal Neoplasms | 1 | 2010 | 64 | 0.10 | Why? |
New York | 1 | 2017 | 2488 | 0.10 | Why? |
Reagent Kits, Diagnostic | 1 | 2020 | 2149 | 0.10 | Why? |
Decontamination | 1 | 2019 | 1196 | 0.10 | Why? |
Suicide, Attempted | 1 | 2016 | 599 | 0.10 | Why? |
Immunization | 1 | 2019 | 2019 | 0.10 | Why? |
Swine | 1 | 2018 | 3352 | 0.10 | Why? |
Kaplan-Meier Estimate | 1 | 2019 | 4260 | 0.10 | Why? |
Exanthema | 1 | 2019 | 1097 | 0.09 | Why? |
Severity of Illness Index | 5 | 2020 | 48226 | 0.09 | Why? |
Meningitis, Bacterial | 1 | 2010 | 111 | 0.09 | Why? |
Hospitals, Teaching | 1 | 2017 | 1609 | 0.09 | Why? |
Dengue | 1 | 2021 | 1565 | 0.09 | Why? |
Prospective Studies | 5 | 2020 | 43301 | 0.09 | Why? |
Hand Disinfection | 1 | 2018 | 1671 | 0.09 | Why? |
Antipsychotic Agents | 1 | 2017 | 887 | 0.09 | Why? |
Hepatitis B | 1 | 2016 | 888 | 0.09 | Why? |
Tomography, X-Ray Computed | 5 | 2018 | 25144 | 0.09 | Why? |
Methylprednisolone | 1 | 2019 | 2107 | 0.09 | Why? |
Heart Defects, Congenital | 1 | 2017 | 933 | 0.09 | Why? |
Antibodies, Viral | 1 | 2020 | 51949 | 0.09 | Why? |
ROC Curve | 3 | 2019 | 6024 | 0.08 | Why? |
Cause of Death | 2 | 2018 | 4823 | 0.08 | Why? |
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 1454 | 0.08 | Why? |
Glasgow Coma Scale | 2 | 2017 | 249 | 0.08 | Why? |
Republic of Korea | 1 | 2020 | 5858 | 0.08 | Why? |
Critical Care | 4 | 2019 | 14081 | 0.08 | Why? |
Hospital Mortality | 7 | 2018 | 22087 | 0.08 | Why? |
World Health Organization | 1 | 2020 | 4213 | 0.08 | Why? |
Lopinavir | 1 | 2021 | 4308 | 0.08 | Why? |
Gram-Negative Bacterial Infections | 1 | 2011 | 398 | 0.08 | Why? |
Health Resources | 1 | 2020 | 2592 | 0.08 | Why? |
DNA, Fungal | 1 | 2006 | 95 | 0.08 | Why? |
Accidental Falls | 1 | 2011 | 448 | 0.08 | Why? |
Ritonavir | 1 | 2021 | 4212 | 0.08 | Why? |
Scleroderma, Systemic | 1 | 2013 | 583 | 0.08 | Why? |
Length of Stay | 3 | 2019 | 11042 | 0.08 | Why? |
Oxygen Inhalation Therapy | 1 | 2019 | 3629 | 0.08 | Why? |
Sleep Initiation and Maintenance Disorders | 1 | 2017 | 1692 | 0.07 | Why? |
Health Personnel | 3 | 2020 | 29646 | 0.07 | Why? |
Chloroquine | 1 | 2020 | 3152 | 0.07 | Why? |
Wounds and Injuries | 1 | 2017 | 1708 | 0.07 | Why? |
Seroepidemiologic Studies | 1 | 2020 | 10017 | 0.07 | Why? |
Disease Progression | 3 | 2018 | 13580 | 0.07 | Why? |
Acute Disease | 1 | 2017 | 6029 | 0.07 | Why? |
Immunologic Factors | 1 | 2020 | 4206 | 0.07 | Why? |
Survival Rate | 1 | 2018 | 9206 | 0.07 | Why? |
Gastrointestinal Diseases | 1 | 2018 | 2580 | 0.06 | Why? |
Transplantation, Homologous | 1 | 2006 | 757 | 0.06 | Why? |
Bone Marrow Transplantation | 1 | 2006 | 343 | 0.06 | Why? |
Logistic Models | 4 | 2017 | 9089 | 0.06 | Why? |
India | 1 | 2020 | 11875 | 0.06 | Why? |
Odds Ratio | 3 | 2019 | 5861 | 0.06 | Why? |
Age Factors | 3 | 2017 | 21039 | 0.06 | Why? |
Radiography, Thoracic | 2 | 2011 | 5486 | 0.06 | Why? |
Cytokines | 2 | 2020 | 15010 | 0.06 | Why? |
Adolescent | 4 | 2020 | 86841 | 0.06 | Why? |
Renal Dialysis | 1 | 2018 | 4358 | 0.06 | Why? |
Fatal Outcome | 2 | 2010 | 3438 | 0.05 | Why? |
Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.05 | Why? |
Treatment Failure | 2 | 2017 | 2106 | 0.05 | Why? |
Sequence Analysis, DNA | 2 | 2010 | 2830 | 0.05 | Why? |
Immunosuppressive Agents | 1 | 2019 | 6331 | 0.05 | Why? |
Population Surveillance | 1 | 2017 | 4967 | 0.05 | Why? |
Animals | 2 | 2021 | 78931 | 0.05 | Why? |
Pleural Effusion | 1 | 2006 | 680 | 0.05 | Why? |
Nervous System Diseases | 1 | 2018 | 4092 | 0.05 | Why? |
Glutathione S-Transferase pi | 1 | 2018 | 10 | 0.05 | Why? |
Sensitivity and Specificity | 1 | 2020 | 22971 | 0.05 | Why? |
Hemochromatosis Protein | 1 | 2018 | 21 | 0.05 | Why? |
Pregnancy | 1 | 2021 | 23879 | 0.05 | Why? |
Asthma | 1 | 2017 | 4383 | 0.05 | Why? |
RNA, Ribosomal, 28S | 1 | 2017 | 13 | 0.05 | Why? |
Glutathione Transferase | 1 | 2018 | 86 | 0.05 | Why? |
Case-Control Studies | 4 | 2017 | 17671 | 0.05 | Why? |
Isoenzymes | 1 | 2018 | 127 | 0.04 | Why? |
Leukocidins | 1 | 2018 | 47 | 0.04 | Why? |
Practice Guidelines as Topic | 2 | 2020 | 15421 | 0.04 | Why? |
Mycological Typing Techniques | 1 | 2017 | 38 | 0.04 | Why? |
Azathioprine | 1 | 2019 | 161 | 0.04 | Why? |
Exotoxins | 1 | 2018 | 54 | 0.04 | Why? |
Biomarkers | 2 | 2018 | 23361 | 0.04 | Why? |
Candida glabrata | 1 | 2017 | 50 | 0.04 | Why? |
Fasciotomy | 1 | 2016 | 23 | 0.04 | Why? |
Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 86 | 0.04 | Why? |
Cyclooxygenase 2 Inhibitors | 1 | 2017 | 48 | 0.04 | Why? |
Disease Outbreaks | 2 | 2020 | 27595 | 0.04 | Why? |
Lipocalin-2 | 1 | 2018 | 156 | 0.04 | Why? |
Restraint, Physical | 1 | 2017 | 74 | 0.04 | Why? |
GPI-Linked Proteins | 1 | 2018 | 317 | 0.04 | Why? |
Injury Severity Score | 1 | 2017 | 287 | 0.04 | Why? |
Thoracic Injuries | 1 | 2017 | 63 | 0.04 | Why? |
Heart Failure | 1 | 2018 | 6638 | 0.04 | Why? |
Fluconazole | 1 | 2017 | 145 | 0.04 | Why? |
Contraindications, Drug | 1 | 2017 | 281 | 0.04 | Why? |
Poisson Distribution | 1 | 2017 | 348 | 0.04 | Why? |
Obesity | 1 | 2017 | 7388 | 0.04 | Why? |
Child | 4 | 2019 | 70012 | 0.04 | Why? |
Bacterial Toxins | 1 | 2018 | 185 | 0.04 | Why? |
beta-Lactam Resistance | 1 | 2017 | 150 | 0.04 | Why? |
Pemphigus | 1 | 2019 | 163 | 0.04 | Why? |
Diagnosis, Differential | 1 | 2011 | 7220 | 0.04 | Why? |
Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
Multivariate Analysis | 2 | 2017 | 5440 | 0.04 | Why? |
Debridement | 1 | 2016 | 172 | 0.04 | Why? |
Azoles | 1 | 2017 | 185 | 0.04 | Why? |
Prednisolone | 1 | 2019 | 443 | 0.04 | Why? |
Carbapenem-Resistant Enterobacteriaceae | 1 | 2018 | 214 | 0.04 | Why? |
Italy | 1 | 2020 | 38444 | 0.04 | Why? |
Young Adult | 4 | 2020 | 93724 | 0.04 | Why? |
Critical Illness | 1 | 2019 | 17281 | 0.04 | Why? |
Chi-Square Distribution | 1 | 2018 | 961 | 0.04 | Why? |
Analysis of Variance | 1 | 2018 | 950 | 0.03 | Why? |
Statistics, Nonparametric | 1 | 2018 | 1008 | 0.03 | Why? |
Public Health | 1 | 2020 | 16359 | 0.03 | Why? |
Salvage Therapy | 1 | 2016 | 417 | 0.03 | Why? |
Microbial Viability | 1 | 2018 | 406 | 0.03 | Why? |
Opportunistic Infections | 1 | 2020 | 602 | 0.03 | Why? |
Infant | 4 | 2019 | 30274 | 0.03 | Why? |
Rectum | 1 | 2017 | 495 | 0.03 | Why? |
Dilatation, Pathologic | 1 | 2013 | 78 | 0.03 | Why? |
Drug Administration Schedule | 1 | 2020 | 2324 | 0.03 | Why? |
Quarantine | 1 | 2020 | 18418 | 0.03 | Why? |
Cross-Sectional Studies | 1 | 2020 | 53120 | 0.03 | Why? |
Enterobacteriaceae | 1 | 2017 | 395 | 0.03 | Why? |
Chest Pain | 1 | 2017 | 578 | 0.03 | Why? |
Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
Pakistan | 1 | 2021 | 2302 | 0.03 | Why? |
Withholding Treatment | 1 | 2019 | 798 | 0.03 | Why? |
Social Responsibility | 1 | 2017 | 363 | 0.03 | Why? |
Cardiovascular Diseases | 1 | 2017 | 11497 | 0.03 | Why? |
Trachea | 1 | 2017 | 894 | 0.03 | Why? |
Hypnotics and Sedatives | 1 | 2017 | 624 | 0.03 | Why? |
Organ Dysfunction Scores | 1 | 2018 | 1475 | 0.03 | Why? |
Streptococcus pneumoniae | 1 | 2016 | 827 | 0.03 | Why? |
Esophagus | 1 | 2013 | 139 | 0.03 | Why? |
Administration, Inhalation | 1 | 2017 | 1647 | 0.03 | Why? |
Hospitalization | 2 | 2019 | 54280 | 0.03 | Why? |
Magnetic Resonance Imaging | 1 | 2007 | 6551 | 0.03 | Why? |
Enoxaparin | 1 | 2017 | 1064 | 0.03 | Why? |
National Health Programs | 1 | 2017 | 807 | 0.03 | Why? |
Sex Factors | 2 | 2017 | 11014 | 0.03 | Why? |
Nasal Mucosa | 1 | 2017 | 1218 | 0.02 | Why? |
Shock, Septic | 1 | 2019 | 1313 | 0.02 | Why? |
Emergency Medicine | 1 | 2019 | 936 | 0.02 | Why? |
Health Care Costs | 1 | 2017 | 1007 | 0.02 | Why? |
Bronchoscopy | 1 | 2017 | 991 | 0.02 | Why? |
Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 1261 | 0.02 | Why? |
Bacterial Typing Techniques | 1 | 2010 | 273 | 0.02 | Why? |
Health Facilities | 1 | 2017 | 1230 | 0.02 | Why? |
Lung | 1 | 2017 | 31049 | 0.02 | Why? |
Heparin, Low-Molecular-Weight | 1 | 2017 | 1731 | 0.02 | Why? |
Child, Preschool | 3 | 2019 | 36283 | 0.02 | Why? |
Multiple Organ Failure | 1 | 2017 | 1724 | 0.02 | Why? |
Infant, Newborn | 2 | 2019 | 23105 | 0.02 | Why? |
Diabetes Complications | 1 | 2019 | 2358 | 0.02 | Why? |
Phenotype | 1 | 2017 | 4037 | 0.02 | Why? |
Genotype | 1 | 2018 | 4697 | 0.02 | Why? |
DNA, Bacterial | 1 | 2010 | 835 | 0.02 | Why? |
Carrier State | 1 | 2017 | 2100 | 0.02 | Why? |
Cardiac Surgical Procedures | 1 | 2018 | 1931 | 0.02 | Why? |
Molecular Sequence Data | 1 | 2010 | 3198 | 0.02 | Why? |
Dyspnea | 1 | 2017 | 3847 | 0.02 | Why? |
Clinical Decision-Making | 1 | 2017 | 3755 | 0.02 | Why? |
Patient Care Team | 1 | 2017 | 3556 | 0.02 | Why? |
Algorithms | 1 | 2019 | 7346 | 0.01 | Why? |
Lung Diseases, Interstitial | 1 | 2013 | 1476 | 0.01 | Why? |
Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
Aging | 1 | 2017 | 3581 | 0.01 | Why? |
Communication | 1 | 2017 | 5206 | 0.01 | Why? |
Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
Models, Theoretical | 1 | 2017 | 6659 | 0.01 | Why? |
Anticoagulants | 1 | 2017 | 9563 | 0.01 | Why? |